From the pr:

“Completing patient recruitment is the initial element, and often the lengthiest, in the conduct of large scale Phase 3 clinical trials,” said Alfred Mann, Chairman and Chief Executive Officer. “Both studies are on track to be completed in the second quarter of 2013 and we expect to report top-line results next summer. Our objective is to resubmit the NDA for AFREZZA in the third quarter of next year.”

Clarification of the timeline coupled with some sort of resolution of the finances should begin the long awaited run-up to approval. We should be pretty close to the end of the cash/ LOC. I expect a pr on how this company will fund to approval in the next few weeks. They might see if this news gives us a lift before they announce some sort of dilution if that is how they intend to fund it.

The next quarterly call should prove to be fairly interesting.

Swing